TORONTO, ON / ACCESSWIRE / May 26, 2017 / Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSX-V: TLT) (OTC PINK: TLTFF), a leading biotechnology company focused on the commercialization of medical devices to eliminate pain and the development of Photo Dynamic Compounds (“PDCs”) to destroy cancer, announced todaythat the independent Data and Safety Monitoring Board (“DSMB”) has unanimously decided that the primary and secondary objectives for the first part of the Phase Ib Non-Muscle Invasive Bladder Cancer (“NMIBC”) clinical study (“Study”) have successfully been met.

Princess Margaret Cancer Centre, University Health Network (“UHN”), in accordance with the DSMB’s decision, is now recommended to enroll an additional six patients for the second part of the Study, treating them at a therapeutic dose of the PDC (0.70 mg/kg) for NMIBC using its novel Photo Dynamic Therapy (“PDT”) technology.

The DSMB is comprised of three highly regarded, independent uro-oncologists; specifically: Dr. Laurence Klotz of Sunnybrook Health Sciences Centre, Dr. Nathan Perlis of the University of Toronto and Dr. Alexandre Zlotta of Mount Sinai Hospital.

The clinical data on the first three patients was presented by Dr. Michael Jewett, Chair of the Medical and Scientific Advisory Board (“MSAB”).

The PDT treatment procedure involves the instillation of a water based solution of Theralase’s lead anti-cancer PDC, TLD-1433, through the urethra into the bladder of the patient, to allow localization of the PDC to the NMIBC. The bladder is then drained of the solution, flushed with sterile water to remove excess solution and refilled with sterile water via a cystoscope. At this point, a fibre optic assembly, known as a Dosimetry Fibre Optic Cage (“DFOC”) with the ability to both emit and detect laser light, is inserted through the cystoscope, to activate the PDC.

The Study is being used to evaluate TLD-1433 for the: primary endpoint of safety and tolerability, secondary endpoint of pharmacokinetics (movement and exit of drug within tissue) and exploratory endpoint of efficacy.

The Study was designed to treat 3 patients at an initial dose of the PDC (0.35 mg/kg) and included initial monitoring for 30 days, according to the endpoint criteria above.

The DSMB members have unanimously recommended that the first three patients enrolled and treated in the Study successfully achieved the primary and secondary endpoints of the Study and an additional six patients are now eligible to be enrolled into the Study to be treated at a therapeutic dose of the PDC and monitored for 180 days, according to the endpoint criteria.

Dr. Michael Jewett, uro-oncologist at UHN stated that, “I am delighted that a small Canadian company, such as Theralase, has been able to achieve such significant clinical results and in such a short time span. I look forward to Theralase reporting out on the next six patients using the therapeutic dose.”

Roger Dumoulin-White, President and CEO of Theralase stated that, “Theralase thanks the DSMB members for their independent review of the clinical data and their decision that the primary and secondary endpoints for the PDT treatment have successfully been achieved for the first three patients in the Study and their recommendation to continue the Study by enrolling an additional six patients to be treated at the therapeutic dose. Theralase looks forward to successfully reporting out on the performance to the primary and secondary endpoints for the next 6 patients and also the exploratory objective of efficacy of all nine patients, as more clinical data is collected. Theralase has now successfully transformed from a pre-clinical to a clinical oncology organization.”

About Theralase Technologies Inc.

Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSX-V: TLT) (OTC PINK: TLTFF) in its Therapeutic Laser Technology (“TLT”) Division designs, manufactures, markets and distributes patented super-pulsed laser technology indicated for the treatment of chronic knee pain, and in off-label use, the elimination of pain, reduction of inflammation and dramatic acceleration of tissue healing for numerous nerve, muscle and joint conditions. Theralase’s Photo Dynamic Therapy (“PDT”) Division researches and develops specially designed molecules called Photo Dynamic Compounds (“PDCs”), which localize to cancer cells and then when laser light activated, effectively destroy them.

Additional information is available at www.theralase.com and www.sedar.com.

This news release contains “forward-looking statements” which reflect the current expectations of management of the Corporation’s future growth, results of operations, performance and business prospects and opportunities. Such statements include, but are not limited to, statements regarding the proposed use of proceeds. Wherever possible, words such as “may”, “would”, “could”, “should”, “will”, “anticipate”, “believe”, “plan”, “expect”, “intend”, “estimate”, “potential for” and similar expressions have been used to identify these forward-looking statements. These statements reflect management’s current beliefs with respect to future events and are based on information currently available to management. Forward-looking statements involve significant risks, uncertainties and assumptions. Many factors could cause the Corporation’s actual results, performance or achievements to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements; including, without limitation, those listed in the filings made by the Corporation with the Canadian securities regulatory authorities (which may be viewed at www.sedar.com). Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward looking statements prove incorrect, actual results, performance or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. These factors should be considered carefully and prospective investors should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in the news release are based upon what management currently believes to be reasonable assumptions, the Corporation cannot assure prospective investors that actual results, performance or achievements will be consistent with these forward-looking statements. The Corporation disclaims any intention or obligation to revise forward-looking statements whether as a result of new information, future developments or otherwise except as required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchanges) accepts responsibility for the adequacy or accuracy of this release.

For More Information:

Roger Dumoulin-White
President & CEO
|1.866.THE.LASE (843-5273) ext. 225
416.699.LASE (5273) ext. 225
rwhite@theralase.com
www.theralase.com

SOURCE: Theralase Technologies Inc.

ReleaseID: 464273

NEW YORK, NY / ACCESSWIRE / May 26, 2017 / Orion Energy Systems, Inc. (NASDAQ: OESX) will be discussing their earnings results in their Q4 Earnings Call to be held May 26, 2017 at 10:00 AM Eastern Time.

To listen to the event live – visit https://www.investornetwork.com/company/23245.

Replay Information

The replay will be available online at https://www.investornetwork.com/company/23245.

About Investor Network

Investor Network (IN) is a new financial content community, serving millions of unique investors market information, earnings, commentary and news on the what’s trending. Dedicated to both the professional and the average traders, IN offers timely, trusted and relevant financial information for virtually every investor. IN is an Issuer Direct brand, to learn more or for the latest financial news and market information, visit www.investornetwork.com. Follow us on Twitter @investornetwork.

SOURCE: Investor Network

ReleaseID: 464251

CANNES, FRANCE / ACCESSWIRE / May 26, 2017 / As buyers, sellers, producers and talent wrap-up activities on the last day of the Cannes Film Festival Marche du Film, U.S. distribution partners Crimson Forest Entertainment Group, Inc. (OTC PINK: CRIM) and Hannover
House, Inc. (OTC PINK: HHSE) have disclosed the first of at least two film production ventures with Silver Lining Productions of London.

“Shimmer” is a live action family-appeal feature about a young boy protecting a Welsh Dragon from nefarious outsiders. The screenplay was written and will be directed by Scott Wheeler, a noted producer and director of science-fiction, fantasy and family films as well as being an acclaimed visual effects master and founder of Rogue State (a U.S.-based post-production facility). Producers will be Grant Bradley (“Singularity”) and Steve Hodges (“Bronte”) along with line producer Erika Steele. Production is slated to occur this summer with principal photography occurring in and around Snowdonia, in Northern Wales. Star casting is now underway.

Executive Producers will include Eric Parkinson, Jonathan Lim and Fred Shefte. Due to the fluid nature of films in a pre-production mode, credits and other production specifics are still subject to potential change.

Crimson Forest and Hannover House have licensed all distribution rights for the USA and English-speaking provinces of Canada for “Shimmer.” A USA theatrical release is planned for Spring 2018.

For more information contact: MaryEvelyn Jones, MeJones@CFF.TV, 479-521-5774

SOURCE: Hannover House, Inc.

ReleaseID: 464311

Thanks to Loan Advisor, People Can Easily Find a Reliable Licensed Money Lender in Singapore

SINGAPORE / ACCESSWIRE / May 26, 2017 / The founders of Loan Advisor, a company that helps match people to a licensed moneylender in Singapore, are pleased to announce the launch of their upgraded website.

To learn more about how Loan Advisor can help people get the personal loan that they need, as well as the three-step process that they use to assist customers in getting the loan, please visit https://www.loanadvisor.sg/.

For people who need a loan, Loan Advisor will help simplify the process in finding a reliable, licensed money lender in Singapore. From families who need money for home repairs to couples who are dealing with a medical or other emergency and need money quickly, Loan Advisor will help them find reliable companies that can assist them.

Using the Loan Advisor website is easy and stress-free; after filling out a simple and quick application form, the website will use the information to match the applicant with the best licensed money lender for his or her needs.

“Customers will get instant loan offers from multiple licensed money lenders in Singapore,” noted a company spokesperson, adding that this service is free and they have made it as quick and easy as possible for people to compare rates from licensed money lenders.

Once applicants have accepted the loan offer they want, they simply need to head down to the licensed money lender’s office to complete the loan process.

As the spokesperson noted, the founders of Loan Advisor understand that applying for a traditional loan from a bank is a lengthy process that typically involves a great deal of paperwork and time. They also know that when people are strapped for cash and need a loan to pay the bills or purchase new tires for the car, they do not have long to wait. This inspired them to launch Loan Advisor, and offer a platform where people can be matched to qualifying moneylenders in Singapore. While they are not a moneylender and do not provide loan services, Loan Advisor is happy to help people find the best moneylender for their needs.

To learn more about the loan comparison website for licensed moneylender loans, please watch a short video on YouTube at https://www.youtube.com/watch?v=RJP0OIGNyqQ.

About Loan Advisor:

Loan Advisor helps match customers to a licensed moneylender in Singapore so as to help them simplify the loan process in finding a reliable loan provider. For more information, please visit https://www.loanadvisor.sg/.

Contact:

Alvin Hines
admin@rocketfactor.com
(949) 555-2861

SOURCE: Loan Advisor

ReleaseID: 464282

Upcoming AWS Coverage on Papa John’s International Post-Earnings Results

LONDON, UK / ACCESSWIRE / May 26, 2017 / Active Wall St. announces its post-earnings coverage on Aramark (NYSE: ARMK). The Company reported its financial results for the second quarter fiscal 2017 (Q2 FY17) on May 09, 2017. The provider of food, facilities and uniform services outperformed earnings estimates. Register with us now for your free membership at:

http://www.activewallst.com/register/

One of Aramark’s competitors within the Specialty Eateries space, Papa John’s International, Inc. (NASDAQ: PZZA), reported on May 02, 2017, its financial results for Q1 ended March 26, 2017. AWS will be initiating a research report on Papa John’s in the coming days.

Today, AWS is promoting its earnings coverage on ARMK; touching on PZZA. Get our free coverage by signing up to:

http://www.activewallst.com/register/

Earnings Reviewed

In Q2 FY17, Aramark reported net sales of $3.62 billion compared to net sales of $3.57 billion prior year. The Company’s revenue numbers met analysts’ consensus of $3.62 billion. Aramark noted that a stronger US dollar decreased sales by approximately $22 million, but had no material impact on operating income or earnings per share.

For the three months ended on March 31, 2017, Aramark’s GAAP operating income totaled $191.42 million compared to $172.11 million in Q2 FY16.

For Q2 FY17, net income attributable to Aramark’s stockholders was $70 million, or $0.28 per diluted earnings share, compared to net income attributable to Aramark’s stockholders of $66 million, or $0.27 per diluted earnings share, in Q2 FY16. In Q2 FY17, the Company’s GAAP diluted earnings per share is increased 4% y-o-y. Furthermore, adjusted net income for the three months ended FY17 was $113 million, or $0.45 per share, versus adjusted net income of $96 million, or $0.39 per share, in Q2 FY16 outperforming Wall Street’s expectations of $0.42 per share.

For the six months ended on March 31, 2017, Aramark’s net sales came in at $7.36 billion, up from $7.29 billion in the year ago same period. Furthermore, net income attributable to Aramark’s stockholders for six months ended FY17 stood at $195.5 million, or $0.78 per diluted share, compared to $159.70 million, or $0.64 per diluted share, in FY16.

Segment performance

During Q2 FY17, Aramark’s FSS North America segment’s net sales totaled $2.56 billion, up 2% compared to $2.52 billion in Q2 FY16. The North America segment was positively impacted by growth in Sports, Leisure and Corrections, Business & Industry, and Education. The segment’s reported operating income increased 11% to $151.97 million compared to operating income of $137.24 million in the prior year’s same quarter.

For Q2 FY17, Aramark’s FSS International sales totaled $674.46 million, gaining 2% compared to sales of $664 million in Q2 FY16, delivering strong, broad-based organic growth. The segment’s operating earnings surged 27% to $31 million in the reported quarter versus $25 million in the year ago comparable period.

Capital Structure & Liquidity

During Q2 FY17, Aramark refinanced approximately $3.5 billion of debt, which extended maturities, improved financial flexibility and lowered expected future interest expense. The Company also increased its revolving credit facility to $1.0 billion in capacity.

The Company’s total trailing 12-month net debt to covenant adjusted EBITDA was 3.7x, a 30 basis point reduction versus the prior year measurement. At quarter-end, Aramark had approximately $1.1 billion in cash and availability on its revolving credit facility.

During the reported quarter, the Company repurchased 2.8 million shares of Aramark’s common stock for an aggregate amount of $100 million. The total remaining share repurchase authorization through the end of 2018 was $150 million.

Outlook

Aramark increased its adjusted EPS forecast by $0.05 per share to a range of $1.90 to $2.00 per share, which includes $0.02 per share of currency headwind. This improved outlook is due to lower interest and tax-related expenses. The Company continues to expect full-year free cash flow of greater than $350 million.

Stock Performance

On Thursday, May 25, 2017, Aramark’s share price finished the trading session at $37.04, marginally up 0.24%. A total volume of 734.84 thousand shares exchanged hands. The stock has surged 3.43% and 12.52% in the last three months and past twelve months, respectively. Furthermore, since the start of the year, shares of the Company have gained 3.70%. The stock is trading at a PE ratio of 28.76 and has a dividend yield of 1.11%.

Active Wall Street:

Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

AWS has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third party research service company (the “Reviewer”) represented by a credentialed financial analyst, for further information on analyst credentials, please email info@activewallst.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.activewallst.com/disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@activewallst.com
Phone number: 1-858-257-3144

Office Address: 3rd floor, 207 Regent Street, London, W1B 3HH, United Kingdom
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active Wall Street

ReleaseID: 464284

Upcoming AWS Coverage on CA Technologies Post-Earnings Results

LONDON, UK / ACCESSWIRE / May 26, 2017 / Active Wall St. announces its post-earnings coverage on Amdocs Ltd (NASDAQ: DOX). The Company announced its second quarter fiscal 2017 financial results on May 09, 2017. The provider of computer systems integration exceeded top- and bottom-line expectations. The company also raised its outlook. Register with us now for your free membership at:

http://www.activewallst.com/register/

One of Amdocs’ competitors within the Business Software & Services space, CA Technologies (NASDAQ: CA), reported on May 11, 2017, its financial results for Q4 FY17 and full FY17, which ended March 31, 2017. AWS will be initiating a research report on CA, Inc. in the coming days.

Today, AWS is promoting its earnings coverage on DOX; touching on CA. Get our free coverage by signing up to:

http://www.activewallst.com/register/

Earnings Reviewed

Amdocs’ revenue for the second fiscal quarter ended March 31, 2017, was $966.01 million, up 4.3% compared to Q2 FY17 revenue of $925.94 million. The Company’s revenue for the reported quarter includes a positive impact from foreign currency movements of approximately $3 million relative to the previous quarter. Amdocs’ revenue was at the midpoint of the Company’s guidance, excluding foreign currency movements and ahead of analysts’ consensus for revenue of $960.7 million.

For Q2 FY17, Amdocs reported GAAP operating income of $134 million, while GAAP operating margin was 13.8% for the reported quarter. The Company’s non-GAAP operating income totaled $166 million, while non-GAAP operating margin was 17.2%

Amdocs’ GAAP net income for Q2 FY17 was $112.6 million, or $0.76 per diluted share, compared to GAAP net income of $107.7 million, or $0.71 per diluted share, in Q2 FY16. The Company’s net income on a non-GAAP basis was $139.2 million, or $0.94 per diluted share, for the reported quarter, compared to non-GAAP net income of $140.2 million, or $0.92 per diluted share, in the prior year’s same quarter. Amdocs’ earnings numbers exceeded Wall Street’s estimates of $0.93 per share.

Cash Matters

On May 09, 2017, Amdocs’ Board approved the Company’s next quarterly cash dividend payment of $0.22 per share and set June 30, 2017, as the record date for determining the shareholders entitled to receive the dividend, which will be payable on July 14, 2017. The Company repurchased $80 million of ordinary shares during Q2 FY17, under its current authorization of $750 million. Amdocs’ have $437 million remaining under authorization as of March 31, 2017.

Amdocs’ free cash flow was $81 million in Q2 FY17, comprising of cash flow from operations of approximately $107 million, less $26 million in net capital expenditures and other, and included an annual cash bonus payment for the prior fiscal year. The Company’s Days Sales Outstanding (DSO) of 80 days decreased by 2 days on a q-o-q basis. Total unbilled receivables increased by $3 million compared to Q1 2017.

Amdocs’ total deferred revenue, both short- and long-term, decreased by $13 million sequentially in the reported quarter. The Company’s cash balance at the end of Q2 FY17 was approximately $1.1 billion, though net of short-term debt, it was $0.9 billion.

Twelve-month Backlog

Amdocs’ twelve-month backlog, which includes anticipated revenue related to contracts, estimated revenue from managed services contracts, letters of intent, maintenance, and estimated on-going support activities, was $3.21 billion at the end of Q2 FY17, up $30 million from the end of the prior quarter.

Outlook

For Q3 FY17, Amdocs is forecasting revenue of approximately $945 million-$985 million, including an immaterial sequential impact from foreign currency fluctuations compared to Q2 FY17. The Company is projecting diluted GAAP EPS of approximately $0.69-$0.77, and diluted non-GAAP EPS of approximately $0.93-$0.99, excluding amortization of purchased intangible assets and other acquisition-related costs and approximately $0.06-$0.07 per share of equity-based compensation expense, net of related tax effects

For full year FY17, Amdocs’ expects revenue growth of 3.5%-5.5% y-o-y on a constant currency basis compared with previous guidance of 2.5%-6.5%. The Company is projecting GAAP diluted earnings per share growth of about 5.0% to 11.0% y-o-y and non-GAAP diluted earnings per share growth of approximately 4.5-8.5% on a y-o-y basis.

Stock Performance

At the close of trading session on Thursday, May 25, 2017, Amdocs’ share price finished the trading session at $64.24, slightly up 0.53%. A total volume of 674.02 thousand shares exchanged hands, which was higher than the 3 months average volume of 619.94 thousand shares. The stock has surged 7.62% and 12.43% in the last six months and past twelve months, respectively. Furthermore, since the start of the year, shares of the Company have rallied 10.28%. The stock is trading at a PE ratio of 23.39 and has a dividend yield of 1.37%.

Active Wall Street:

Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

AWS has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third party research service company (the “Reviewer”) represented by a credentialed financial analyst, for further information on analyst credentials, please email info@activewallst.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.activewallst.com/disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@activewallst.com
Phone number: 1-858-257-3144

Office Address: 3rd floor, 207 Regent Street, London, W1B 3HH, United Kingdom

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active Wall Street

ReleaseID: 464283

Upcoming AWS Coverage on Smart & Final Stores Post-Earnings Results

LONDON, UK / ACCESSWIRE / May 26, 2017 / Active Wall St. announces its post-earnings coverage on Whole Foods Market, Inc. (NASDAQ: WFM). The Company announced its second quarter fiscal 2017 financial results on May 10, 2017. The grocery chain revenue increased 1.1% on a y-o-y basis and also announced board reshuffling with a change in CFO. Register with us now for your free membership at: http://www.activewallst.com/register/.

One of Kroger’s competitors within the Grocery Stores space, Smart & Final Stores, Inc. (NYSE: SFS), reported on May 03, 2017, its financial results for the fiscal first quarter ended March 26, 2017. AWS will be initiating a research report on Smart & Final Stores in the coming days.

Today, AWS is promoting its earnings coverage on WFM; touching on SFS. Get our free coverage by signing up to:
http://www.activewallst.com/register/.

Earnings Reviewed

For the 12-week second quarter ended April 09, 2017, Whole Foods’ total sales increased 1.1% to a record $3.74 billion compared to net sales of $3.70 billion in Q2 FY16. The Company’s revenue numbers surpassed analysts’ consensus of $3.73 billion. Including an estimated negative impact of 30 basis points from Easter shifting from Q2 FY16 to Q3 FY17, comparable store sales decreased 2.8%.

For Q2 FY17, Whole Foods’ gross margin declined 82 basis points to 34.1% driven by increases in occupancy costs and cost of goods sold as a percentage of sales. LIFO charges were $3 million versus $2 million last year, a negative impact of three basis points. The Company’s earnings before interest, taxes, depreciation, and amortization (EBITDA) were $287 million, or 7.7% of sales, for the reported quarter.

Whole Foods reported net income of $99 million, or diluted earnings per share, of $0.31 for Q2 FY17 compared to net income of $142 million, or diluted earnings per share of $0.44. The Company’s results included a charge of $30 million, or $0.06 per diluted share, related to previously-announced store and facility closures. Excluding this charge, Whole Foods net income was $117 million, or diluted earnings per share of $0.37, matching Wall Street’s estimates of $0.37 per share.

During Q2 FY17, Whole Foods produced operating cash flow of $340 million, free cash flow of $209 million, and returned $45 million in dividends to shareholders, ending the reported quarter with $1.4 billion of total available capital and $1.0 billion in total debt.

CFO Change

In a separate press release on May 10, Whole Foods announced the appointment of Keith Manbeck as Executive Vice President and Chief Financial Officer (CFO), effective May 17, 2017. Mr. Manbeck will join a leadership team that is implementing an accelerated plan to enhance shareholder value in a dynamic and increasingly competitive marketplace.

Mr. Manbeck brings to Whole Foods Market more than 20 years of financial and operational experience at leading companies, most recently serving as Senior Vice President of Digital Finance, Strategy Management and Business Transformation at Kohl’s Corporation since 2014.

New Board Leadership and 5 New Independent Directors

On May 10, 2017, Whole Foods announced a significant reshuffling of its Board of Directors by appointing five new independent directors, effective immediately:

1) Ken Hicks, former Chairman, President, and Chief Executive Officer of Foot Locker;
2) Joe Mansueto, Founder and Executive Chairman of Morningstar;
3) Sharon McCollam, the former Executive Vice President, Chief Administrative and Chief Financial Officer of Best Buy;
4) Scott Powers, who held leadership positions at State Street Corporation from 2008 to 2015;
5) Ron Shaich, Founder, Chairman, and Chief Executive Officer of Panera Bread Company.

The Company also announced that Gabrielle Sulzberger has been appointed the new Chair of the Whole Foods Market Board of Directors and Mary Ellen Coe has been appointed the new Chair of the Nominating & Governance Committee.

With these changes, the Whole Foods Market’s Board of Directors will be comprised of 12 directors, 10 of whom are independent, and out of the 10, 6 were added in the last seven months.

Growth and Development

In Q2 FY17, Whole Foods opened six stores, including two relocations, and closed nine stores, as previously announced. The Company also closed one store for a major remodel and one store that will be relocated in the fourth quarter. So far in the third quarter, the Company has opened three stores, including one Whole Foods Market 365 store. Whole Foods expects to open three additional stores including one relocation during the coming quarter.

Returning Capital to Shareholders

Whole Foods’ Board of Directors announced a 29% increase in the regular quarterly dividend to $0.18 per share and authorized a new $1.25 billion share repurchase program, with the intent to opportunistically utilize the authorization over the next 18 months. The new authorization will replace the Company’s existing program. The next quarterly dividend to be declared is expected to be paid on July 11, 2017, to shareholders of record as of June 30, 2017.

Updated Outlook

For FY17, Whole Foods is projecting sales growth of 1% or greater and expects comps to decline as much as 2.5%. The Company is estimating EBITDA margin of approximately 8% and diluted earnings per share of $1.30 or more for the fiscal year.

Longer-term Targets

The Company expects to return to positive comparable store sales and earnings growth by the end of fiscal year 2018. In addition, based on the implementation of new and accelerated initiatives, for fiscal 2020, Whole Foods envisions total sales of more than $18 billion, comps growth of over 2%, EBITDA margin of above 9.5%, and cash flow from operations greater than $1.2 billion.

Stock Performance

On Thursday, May 25, 2017, the stock closed the trading session flat at $35.32, with a total volume of 3.56 million shares traded. Whole Foods Market’s stock price surged 11.91% in the last three months, 13.72% in the past six months, and 10.17% in the previous twelve months. Furthermore, since the start of the year, shares of the Company have rallied 14.82%. The stock is trading at a PE ratio of 25.54 and has a dividend yield of 2.04%.

Active Wall Street:

Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

AWS has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third party research service company (the “Reviewer”) represented by a credentialed financial analyst, for further information on analyst credentials, please email info@activewallst.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.activewallst.com/disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@activewallst.com
Phone number: 1-858-257-3144

Office Address: 3rd floor, 207 Regent Street, London, W1B 3HH, United Kingdom

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active Wall Street

ReleaseID: 464300

Upcoming AWS Coverage on Tetra Tech Post-Earnings Results

LONDON, UK / ACCESSWIRE / May 26, 2017 / Active Wall St. announces its post-earnings coverage on Jacobs Engineering Group Inc. (NYSE: JEC). The Company released its second quarter fiscal 2017 financial results on May 09, 2017. The construction and technical services Company reported better than expected earnings. Register with us now for your free membership at: http://www.activewallst.com/register/.

One of Jacobs Engineering Group’s competitors within the Technical Services space, Tetra Tech, Inc. (NASDAQ: TTEK), reported on May 03, 2017, its financial results for Q2 ended April 02, 2017. AWS will be initiating a research report on Tetra Tech in the coming days.

Today, AWS is promoting its earnings coverage on JEC; touching on TTEK. Get our free coverage by signing up to:
http://www.activewallst.com/register/.

Earnings Reviewed

For the three months ended March 31, 2017, Jacobs revenue totaled $2.31 billion, down compared to revenue of $2.78 billion in Q2 FY16. On an adjusted basis, the Company reported revenue of $2.32 billion. Jacobs’ revenue numbers fell short of analysts’ consensus of $2.61 billion.

For Q2 FY17, Jacobs reported gross margin improvement of over 200 basis points versus the prior year, driven by strong project execution and increased focus on more profitable business. The Company noted that as a result of both the margin improvement and cost efficiency, the reported quarter adjusted operating profit of $140 million improved by $18.4 million versus Q2 FY16 and on an adjusted operating profit margin basis, an increase of 165 basis points versus the year earlier same quarter.

Jacobs reported GAAP net earnings of $50 million, or $0.41 per share for Q1 2017 compared to GAAP net earnings of $65 million, or $0.54 per share, for Q2 FY16. The Company’s reported quarter results include approximately $45 million, or $0.37 per share, in after-tax costs associated with its 2015 restructuring as well as other charges associated with the strategic review of its Europe, UK, and Middle-East regional operations. Excluding the restructuring and other charges, Jacobs’ Q2 FY17 adjusted net earnings totaled $95 million, or $0.78 per share, up 4% compared to $91 million, or $0.75 per share, from the corresponding period for 2016. The Company’s earnings exceeded Wall Street’s estimates of $0.71 per share.

Segment Results

For Q2 FY17, Jacobs’ Buildings & Infrastructure business’ sales improved 1.1% on a y-o-y basis to $585.2 million. The segment’s operating profit grew 3.6% versus the year-ago comparable period to $43.99 million, and operating profit margin increased 18 basis points to 7.5%.

Jacobs’ Industrial line of business, meanwhile, saw a 23% decline to $582.46 million, driven in part by the recent completion of several projects and prior to the mobilization on several new field services projects. The overall operating profit for the group improved versus Q2 FY16 due to the year-ago same period being impacted by a litigation settlement and customer bankruptcy. Consequently, operating profit for the group increased by 94% versus the year ago corresponding quarter to $24 million, and operating profit margin rose a significant 227 basis points to 4.1%.

During Q2 FY17, Jacobs’ revenues from Petroleum & Chemicals (P&C) segment slumped 36% to $557.8 million, and continued to experience revenue weakness due to cyclical softness in the industry, primarily driven by lower field service activity. At the operational level, however, the impact of the reduction in revenue was more than offset by a onetime benefit associated with the restructuring of the Company’s P&C-related Indian welfare trust program of $9.9 million and its focus on improving margin mix and project execution. These combined to support a significant 281 basis point improvement on operating profit margin to 6.4%. The Company’s Aerospace & Technology segment’s Q2 FY17 revenue dropped 14% to $577.04 million.

Backlog

As of March 31, 2017, Jacobs’ total backlog was $18.5 billion, including a professional services component of $12.4 billion, compared to total backlog of $18.2 billion and a professional services component of $11.4 billion for the corresponding period last year. The Company reported book-to-bill ratio of 1.02 for a trailing 12-month period, up from 0.94 in the year ago same period.

Cash Matters

Jacobs’ cash flow from operations was $96 million in Q2 FY17. Additionally, during the reported quarter, the Company repurchased 0.9 million shares of its common stock at a total cost of $51 million and paid dividends of $18 million.

On May 05, 2017, Jacobs announced that its Board of Directors has approved and declared a quarterly cash dividend to shareholders. A quarterly dividend of $0.15 per share of Jacobs’s common stock will be paid on June 16, 2017, to shareholders of record on the close of business on May 19, 2017.

Outlook

The Company stated that given its Q2 FY17 and year to date results, its expectations remain unchanged for the year, with a range of total adjusted EPS for the year at $3.00 to $3.30 per share.

Stock Performance

At the close of trading session on Thursday, May 25, 2017, Jacobs Engineering’s stock price marginally declined 0.66% to end the day at $52.59. A total volume of 841.46 thousand shares were exchanged during the session. The Company’s share price has gained 5.14% in the past twelve months. The Company’s shares are trading at a PE ratio of 30.56 and have a dividend yield of 1.14%. The stock currently has a market cap of $6.28 billion.

Active Wall Street:

Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

AWS has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third party research service company (the “Reviewer”) represented by a credentialed financial analyst, for further information on analyst credentials, please email info@activewallst.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.activewallst.com/disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@activewallst.com
Phone number: 1-858-257-3144

Office Address: 3rd floor, 207 Regent Street, London, W1B 3HH, United Kingdom

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active Wall Street

ReleaseID: 464304